Homology Medicines, Inc. (FIXX): Price and Financial Metrics


Homology Medicines, Inc. (FIXX)

Today's Latest Price: $13.00 USD

0.04 (-0.31%)

Updated Jan 27 8:58am

Add FIXX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

FIXX Stock Summary

  • Homology Medicines Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 9.58% of US listed stocks.
  • FIXX's went public 2.84 years ago, making it older than just 8.05% of listed US stocks we're tracking.
  • FIXX's price/sales ratio is 258.31; that's higher than the P/S ratio of 97.85% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Homology Medicines Inc, a group of peers worth examining would be EVGN, ARCT, GRTS, AUTL, and QURE.
  • Visit FIXX's SEC page to see the company's official filings. To visit the company's web site, go to www.homologymedicines.com.

FIXX Stock Price Chart Interactive Chart >

Price chart for FIXX

FIXX Price/Volume Stats

Current price $13.00 52-week high $22.38
Prev. close $13.04 52-week low $8.70
Day low $13.00 Volume 304
Day high $13.00 Avg. volume 282,459
50-day MA $11.36 Dividend yield N/A
200-day MA $12.49 Market Cap 588.43M

Homology Medicines, Inc. (FIXX) Company Bio


Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.


FIXX Latest News Stream


Event/Time News Detail
Loading, please wait...

FIXX Latest Social Stream


Loading social stream, please wait...

View Full FIXX Social Stream

Latest FIXX News From Around the Web

Below are the latest news stories about Homology Medicines Inc that investors may wish to consider to help them evaluate FIXX as an investment opportunity.

Homology Medicines unveils plans to start three gene therapy programs this year

Homology Medicines ([[FIXX]] +4.3%) has outlined plans to initiate two additional Phase 1/2 dose-escalation trials in 2021 with its gene therapy candidate for Hunter syndrome and gene editing candidate, which is for Phenylketonuria ((PKU)).Additionally, the company plans to name another development candidate focused on a new therapeutic indication during this year.Last year in...

Seeking Alpha | January 6, 2021

Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)

\- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - \- Company Plans to Nominate Additional Development Candidate in New Therapeutic Area - \- Management Highlights Anticipated 2021 Milestones in Webcast Available on Homology’s Website -BEDFORD, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today plans to progress its gene therapy and gene editing platform, and unveiled plans to have three clinical programs and a development candidate in a new therapeutic area during 2021.“We ended 2020 with positive data from the dose-escalation phase of the world’s first PKU gene therapy clinical trial, pheNIX, and validation of both our PKU gene...

Yahoo | January 6, 2021

Alexion, Calyxt, Arvinas: 5 Top Stock Gainers for Monday

Alexion Pharmaceuticals, Calyxt, Homology Medicines, Arvinas and SandRidge Energy are five top stock gainers for Monday.

The Street | December 14, 2020

Oppenheimer Says These 2 Stocks Could Spike Over 100%

Markets have been turning mostly up since the election, as investors have taken the measure of the macro environment and appear pleased. There is some expectation that political matters may settle down, allowing government, public health officials, and the business world to focus on beating the next wave of the coronavirus pandemic. The big news on that front, of course, came from Pharma giants Pfizer and Moderna, which have both announced success in trial phases of COVID vaccines, and are currently on the cusp of gaining emergency use authorization (EUA). The prospect of an early vaccine is bullish for the markets, and has investors looking forward.

Michael Marcus on TipRanks | December 11, 2020

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims. Relevant Period: Before July 21, 2020 Visit: www.hbsslaw.com/investor-fraud/FIXX Contact An Attorney Now: [email protected] 844-916-0895Homology Medicines, Inc. (FIXX) Investigation:Homology Medicines is a Boston, MA-based gene therapy company focused on curing rare genetic diseases.The investigation centers on the accuracy of Homology Medicines’ statements concerning the efficacy of its first and lead product candidate, HMI-102, which purportedly treats a rare inherited disorder that causes an amino acid called phe...

Yahoo | November 10, 2020

Read More 'FIXX' Stories Here

FIXX Price Returns

1-mo 5.61%
3-mo 17.12%
6-mo -1.14%
1-year -15.58%
3-year N/A
5-year N/A
YTD 15.15%
2020 -45.46%
2019 -7.42%
2018 N/A
2017 N/A
2016 N/A

Continue Researching FIXX

Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:

Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1043 seconds.